IDXX · 8-K · 20261102PR120892
Guidance / Outlook
IDEXX LABORATORIES INC /DE · 2026-11-02 · Importance 66 · Surprise 60 · No source text
IDEXX raised its 2026 revenue outlook to $4,741–$4,767 million and organic revenue growth to 9.3%–10.0%, increases of $32 million and 0.6 percentage points at the respective midpoints. CAG Diagnostics recurring revenue growth is projected at 11.0%–11.7% reported and 10.3%–11.0% organic. The company lowered its operating-margin outlook to 32.1%–32.3%, with 50–70 basis points of reported and comparable expansion, and raised EPS guidance to $14.96–$15.16. It projects 2026 capital expenditures of approximately $160 million, down from prior guidance of approximately $180 million.
Key facts
- IDEXX increased its 2026 revenue guidance to $4,741 million–$4,767 million, up $32 million at the midpoint, reflecting strong CAG Diagnostics recurring revenue performance. source
- IDEXX raised its 2026 EPS outlook to $14.96–$15.16, a $0.25 increase over the prior guidance midpoint, led by a higher revenue outlook while supporting acquisition impacts. source
- IDEXX raised 2026 reported revenue growth guidance to 10.1%–10.8% and CAG Diagnostics recurring revenue reported growth guidance to 11.0%–11.7%; projected organic revenue growth is 9.3%–10.0% and CAG Diagnostics recurring revenue organic growth is 10.3%–11.0%. source
- IDEXX updated its EPS outlook to $14.96–$15.16, $0.25 above the prior guidance midpoint, reflecting 15% reported and 16% comparable growth. source
- IDEXX's 2026 EPS outlook is $14.96–$15.16, compared with prior outlook of $14.69–$14.94. source
- IDEXX lowered its full-year 2026 reported operating margin outlook to 32.1%–32.3%, with projected operating profit margin expansion of 50–70 basis points reported and comparable; updated guidance includes acquisition-related impacts. source
- IDEXX's 2026 outlook includes CAG Diagnostics recurring revenue growth of 11.0%–11.7% reported and 10.3%–11.0% organic. source
- IDEXX's 2026 outlook projects reported and comparable operating margin expansion of 50–70 basis points, compared with prior outlook of 70–90 basis points for each. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | positive | committed | +0.5% | IDEXX projects 2026 capital expenditures of approximately $160 million, compared with prior outlook of approximately $180 million. |
| margin | negative | committed | -0.2% | IDEXX's 2026 outlook projects reported and comparable operating margin expansion of 50–70 basis points, compared with prior outlook of… |
| net_income | positive | committed | — | IDEXX's 2026 EPS outlook is $14.96–$15.16, compared with prior outlook of $14.69–$14.94. |
| cash | positive | committed | — | IDEXX's 2026 outlook projects free cash flow at 95%–100% of net income, compared with prior outlook of 90%–100%. |